US 12,152,084 B2
Triple combination antibody therapies
Spencer Liang, Belmont, CA (US); Ling Leung, Foster City, CA (US); Sarah Whelan, Mountain View, CA (US); Maya Kotturi, Belmont, CA (US); Eran Ophir, Yehuda (IL); Arthur Machlenkin, Givaat Brener (IL); Zoya Alteber, Nes Ziyona (IL); Meir Azulay, Givatayim (IL); Sandeep Kumar, San Bruno, CA (US); Radhika Desai, Brisbane, CA (US); Christopher Chan, South San Francisco, CA (US); and Kathryn Logronio, Pleasanton, CA (US)
Assigned to COMPUGEN LTD., Holon (IL)
Filed by Compugen Ltd., Holon (IL)
Filed on Dec. 7, 2021, as Appl. No. 17/544,852.
Application 17/544,852 is a continuation of application No. 15/996,369, filed on Jun. 1, 2018, granted, now 11,225,523.
Claims priority of provisional application 62/618,005, filed on Jan. 16, 2018.
Claims priority of provisional application 62/582,756, filed on Nov. 7, 2017.
Claims priority of provisional application 62/547,051, filed on Aug. 17, 2017.
Claims priority of provisional application 62/538,563, filed on Jul. 28, 2017.
Claims priority of provisional application 62/515,452, filed on Jun. 5, 2017.
Claims priority of provisional application 62/513,960, filed on Jun. 1, 2017.
Prior Publication US 2023/0070685 A1, Mar. 9, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); A61K 38/17 (2006.01); C07K 16/24 (2006.01); C07K 16/42 (2006.01); G01N 33/574 (2006.01)
CPC C07K 16/3061 (2013.01) [A61K 39/395 (2013.01); A61P 35/00 (2018.01); C07K 16/28 (2013.01); C07K 16/2803 (2013.01); A61K 38/1709 (2013.01); A61K 2300/00 (2013.01); C07K 16/24 (2013.01); C07K 16/2875 (2013.01); C07K 16/4283 (2013.01); G01N 33/57484 (2013.01)] 12 Claims
 
1. A method of treatment for cancer in a patient comprising administering the triple combination comprising an anti-TIGIT antibody, an anti-PVRIG antibody and an anti-PD-1 antibody, wherein said anti-TIGIT antibody is an antibody chosen from at least one of CPA.9.083.H4(S241P), CPA.9.086.H4(S241P), CHA.9.547.7.H4(S241P) and CHA.9.547.13.H4(S241P).